Collectionner le produit
Détails du produit
Synonyms
Delta3, delta-like 3 (Drosophila), delta-like protein 3, DLL3, Pudgy, SCDO1, SCDO1delta3
Source
Biotinylated Cynomolgus DLL3, His,Avitag (DL3-C82E9) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 488 (Accession # A0A2K5WSR1-1).
Predicted N-terminus: Ala 27
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 51.7 kDa. The protein migrates as 47-52 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the SABA assay / HABA assay / binding ELISA.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Biotinylated Cynomolgus DLL3, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA
Immobilized Biotinylated Cynomolgus DLL3, His,Avitag (Cat. No. DL3-C82E9) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-DLL3 Antibody (specific Binding DSL of DLL3), Human IgG1 with a linear range of 0.1-1 ng/mL (Routinely tested).
Protocol
Immobilized Biotinylated Cynomolgus DLL3, His,Avitag (Cat. No. DL3-C82E9) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-DLL3 Antibody (specific Binding EGFs of DLL3), Human IgG1 with a linear range of 0.2-2 ng/mL (Routinely tested).
Protocol
Bioactivity-SPR
Anti-DLL3 Antibody (specific Binding DSL of DLL3), Human IgG1 captured on Protein A Chip can bind Biotinylated Cynomolgus DLL3, His,Avitag (Cat. No. DL3-C82E9) with an affinity constant of 3.61 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Delta-like protein 3
- Catégorie：
- Nombre de médicaments répertoriés：
1 Détails
- Nombre de médicaments cliniques：
28 Détails
- Étape de développement la plus élevée：
Approved
Contact Us
Drug Candidate Licensing
